OTCQB: IZOZF
CSE: IZO
FSE: 1R3
Home
IzoView
Presentations
Breast CT Clinical Data
Media
Images
Videos
Podcast
News
Team
Team Fact Sheets
Management
Advisors
Investors
Investor Presentation
Why Invest in IzoView Breast CT?
Stock Info
Financials
FAQ
Frequently Asked Questions
Contact
Menu
Investors
Financials
2025
September 29, 2025
For the Three Months Ended July 31, 2025
FS
MDA
August 29, 2025
For the Twelve Months Ended April 30, 2025
FS
MDA
April 1, 2025
For the Nine Months Ended January 31, 2025
FS
MDA
2024
December 30, 2024
For the Six Months Ended October 31, 2024
FS
MDA
Investor Presentation
Why Invest in IzoView Breast CT?
Stock Info
Financials
IzoView
Presentations
Breast CT Clinical Data
Media
Images
Videos
Podcast
News
AI in Breast Imaging: New BreastCT.com Article Examines IzoView’s Competitive Edge
Izotropic’s IzoView Breast CT the First in Category to Offer Patent-Pending Personalized Radiation Dose
Izotropic Closes Non-Brokered Private Placement and Engages Awareness Consultants
Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-Makers
Izotropic Gains Visibility as AI Market Broadens Beyond Tech
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Robert Thast, CEO of Izotropic Corp.
Izotropic Secures Exclusive Rights to Patented Computer-Aided Diagnosis for Breast CT
Izotropic’s AI Breakthrough Positions IzoView to Redefine Breast CT Imaging Standards
Izotropic Announces Non-Brokered Private Placement & Extends Warrants
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView Device
Izotropic Introduces New Corporate Website & Brand Identity
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
Izotropic’s IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers
Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies
Izotropic Provides Marketing Update
Izotropic Updates License Agreement Terms with University of California
Izotropic’s U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
Izotropic to Present at Investor Conference March 13th
FDA Sets Meeting Date with Izotropic
Izotropic Closes Non-Brokered Private Placement
Izotropic Announces Non-Brokered Private Placement- February 2025
Izotropic Announces Timelines and Milestones to IzoView Product Launch
Izotropic Featured in Announcement of Research and Markets’ U.S. Breast Cancer Analysis and Forecast
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening
Team
Team Fact Sheets
Management
Advisors
Investors
Investor Presentation
Why Invest in IzoView Breast CT?
Stock Info
Financials
FAQ
Frequently Asked Questions
Contact
